Incyte reports Q4 EPS $1.46, consensus $1.55

Reports Q4 revenue $1.18B, consensus $1.15B. “2024 was an important year for Incyte (INCY), with a 15% increase in total revenues, driven by strong growth from both Jakafi and Opzelura, as well as significant progress across our R&D pipeline,” said Herve Hoppenot, CEO, Incyte. “Looking ahead to 2025, we anticipate a year of continued strong revenue growth and diversification, as well as several defining milestones that will serve as an inflection point for Incyte. A year ago, we set the goal to achieve more than 10 impactful product launches by 2030. In 2025, a number of key catalysts across the entire portfolio will bring that goal closer to reality.”